

Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Gail Darling

Name of drug and indication under review: Pembrolizumab/ 1L NSCLC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

	Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes ☑ No						
	If no, p	please go to Section B.					
2. What form of payment did you receive? (Check all that apply.)							
		Advisory role (e.g., advisory boards, HTA submission advice) Conference attendance		Program or Operating Funding (e.g., website) Research/educational grants			
		Royalties		Travel grants			
		Gifts Honoraria		Sponsorship of Events			
		Other, please specify: Click here to ent	er text.				
3.		e provide the names of companies and box below.	l organi	zations and the amounts of the payments			
Clid	ck here	to enter text.					



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

n/a

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: October 1st 2017

Name: Gail Darling

Signature:



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: STACEY HUBAY

Name of drug and indication under review: Pembrolizumab/1L NSCLC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

			d any payments over the		two years from any company or tin the drug under review?	
	If no, please go to Section B.					
2.	. What form of payment did you receive? (Check all that apply.)					
		HTA submit Conference Royalties Gifts Honoraria	le (e.g., advisory boards, ssion advice) attendance se specify: Click here to en	der text.	Program or Operating Funding (e.g., website) Research/educational grants Travel grants Sponsorship of Events	
	in the l	provide the box below. to enter text.	•	nd organiz	cations and the amounts of the payme	ents



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

No.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

NO.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: September 7th, 2018

Name:

Stacey Hubay

Signature:

Click pere to enter text.



1

Appendix A: pCODR Clinician Conflict of Interest Declarations

Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:		Mark D Vincent MD FRCPC				
N	Name of drug and indication under review:	Pembrolizumab nonsmall cell lung cancer				
Со	onflict of Interest Declaration					
con of ir	nflicts of interest. A registered clinician must decl	ODR process, all participants in the pCODR review process must disclose any lare any potential conflicts of interest that may influence or have the appearance of interest declaration is requested for transparency — it does not negate or				
Exa	amples of conflicts of interest include, but are no	ot limited to:				
	financial support from the pharmaceutical indust gifts, and salary)	try or other entities (e.g., educational or research grants, honoraria,				
• ;	affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.					
Sec	ction A: Payment Received					
 Have you received any payments over the previous two years from any company or organization that may have a direct indirect interest in the drug under review? 						
	⊠ Yes □ No					
	If no, please go to Section B.					
2. What form of payment did you receive? (Check all that apply.)		k all that apply.)				
	Advisory role (e.g., advisory boards, hea technology assessment submission advi					
	☐ Conference attendance	☐ Research/educational grants				
	☐ Royalties	☐ Travel grants				
	☐ Gifts	☐ Sponsorship of events				
	☐ Honoraria	☐ Other, please specify:				
3.	Please provide the names of companies and organizations, and the amounts of the payments, in the following box.					
		honoraria (probably up to 4 occasions. Usual fee each time (as I recall about e slightly inaccurate as it is from memory.				



Section B: Holdings or Other Interests

	ession of stocks or options of more the rest in the drug under review? If yes,	nan \$10,000 (excluding mutual funds) for organizations that please list them in the following box.
No		
Do you have personal or commer parent corporation, subsidiaries, a	· · · · · · · · · · · · · · · · · · ·	r health technology manufacturer (including the manufacturer's s) or other interest groups? If yes, please provide the names of
No; but I do attend occasional	ad boards of other companies that al	so have drugs that might be competitors in the future.
hereby certify that I have disclos potential, or perceived conflict of		ect to any matter involving a Party that may place me in a real,
28 September 2018	Mark D Vincent	Muient
Date	Name	Signature